A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Injectable GLP-1 drugs for obesity have been found to produce smaller weight loss in a real-world setting compared to ...

“In real-world terms, that means many patients ... “We now have more than one highly effective option, and Zepbound seems to be leading the pack,” he said. An important implication, for ...

Weight-loss medications continue to grow in popularity as an anti-obesity tool — but are some more effective than others ... of tirzepatide (brand name Zepbound) and semaglutide (brand name ...

side effects and supply shortages Weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting, according to a new study. The study — published June 10 in ...

But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness ...

WEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs ...

“The results highlight a need for real-world comparative effectiveness data of CPAP ... the U.S. Food and Drug Administration (FDA) approved Zepbound as the first drug to treat people with ...